Vital Therapies, Inc. Expands Board of Directors

Vital Therapies, Inc. Expands Board of Directors 
SAN DIEGO, CA -- (Marketwired) -- 09/20/13 --  Vital Therapies(R),
Inc. (VTI), a biopharmaceutical company developing a cell-based
therapy targeting the treatment of acute liver failure, today
announced election of Jean-Jacques Bienaime to the company's Board of
Jean-Jacques Bienaime is the Chief Executive Officer and a member of
the Board of Directors of BioMarin(R) Pharmaceutical Inc., (NASDAQ:
BMRN), a market-leader in the development and commercialization of
innovative biopharmaceuticals for serious diseases and medical
conditions. The company's product portfolio comprises four approved
orphan drug products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme(R) (galsulfase) for
mucopolysaccharidosis VI, Kuvan(R) (sapropterin dihydrochloride) for
phenylketonuria, Aldurazyme(R) (laronidase) for mucopolysaccharidosis
I, and Firdapse(TM) (amifampridine phosphate) for Lambert-Eaton
myasthenic syndrome. 
Under Mr. Bienaime's leadership BioMarin's market capitalization has
grown from its May 2005 value of $450 million to its current value of
$11 billion. The company generated $500.7 million in revenue in 2012,
a 13.4% increase over the prior 12 months.  
Mr. Bienaime is a member of the board of directors of InterMune, Inc.
(NASDAQ: ITMN), a member of the board of directors of Portola
Pharmaceuticals, Inc. (NASDAQ: PTLA), and a member of the board of
directors for Biotechnology Industry Organization. He received an
M.B.A from the Wharton School at the University of Pennsylvania and a
degree in economics from the Ecole Superieure de Commerce de Paris. 
Muneer Satter, VTI's Co-Chairman and Lead Director said, "We are
delighted to have Mr. Bienaime's invaluable guidance on our Board of
Directors. BioMarin is a true innovator in the development and
marketing of orphan biologic therapies. We welcome JJ's expert advice
as we enter our phase 3 trials and soon begin preparations for
potential commercialization."  
About Vital Therapies Inc 
Vital Therapies, Inc. is a private biopharmaceutical company
developing a cell-based therapy targeting the treatment of acute
liver failure. The company's lead product-candidate, ELAD, is an
extra-corporeal bio-artificial liver currently in phase 3 clinical
trials. VTI is based in San Diego, California.  
About ELAD 
ELAD is a Phase 3 investigational extracorporeal bio-artificial liver
therapy designed to supplement hepatic function in order to improve
survival rates among patients with acute liver failure. ELAD consists
of a re-usable bedside unit attached to four disposable cartridges,
which collectively contain thousands of hollow fibers and
approximately one pound of immortal human C3A cells from our
proprietary cell bank. The patient's plasma flows inside of the
hollow fibers to allow two-way transfer of metabolites. The system
has been shown to process toxins, and synthesize proteins and
metabolites in ways that mimic components of normal human liver
function. The ELAD cell cartridges are produced at VTI's
GMP-compliant facility in San Diego, California. Moreover, the
therapy has received Orphan Designation in both the United States and
Europe for the treatment of acute liver failure. 
Vital Therapies(R) and ELAD(R) are trademarks of Vital Therapies,
BioMarin(R), Naglazyme(R), Kuvan(R) and Firdapse(TM) are registered
trademarks of BioMarin Pharmaceutical Inc. 
Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. 
This press release may contain forward-looking statements, including
but not limited to statements regarding current and future clinical
studies in our Phase 3 program and ELAD's potential market launch.
These statements relate to future events and are subject to risks,
uncertainties and assumptions about Vital Therapies, Inc. These
statements are only predictions based on our current expectations and
projections about future events. You should not place undue reliance
on these statements. Actual events or results may differ materially.
Many factors may cause our actual results to differ materially from
any forward-looking statement. We do not undertake to update any
forward-looking statements. 
Terry Winters
Co-Chairman & Chief Executive Officer
Duane Nash
Chief Business Officer
Vital Therapies, Inc.
Press spacebar to pause and continue. Press esc to stop.